Plain-English translation of NCT04823403 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new way to treat advanced liver cancer using two immunotherapy medications: and . will be injected directly into the blood vessels supplying your liver tumor (a one-time injection), while will be given as a regular intravenous infusion. The study wants to find the safest and most effective dose of this combination treatment.
Standard treatments for advanced liver cancer that cannot be surgically removed have limited effectiveness. This trial is exploring whether delivering one of the medications directly to the tumor site, combined with the other medication given through the bloodstream, might work better and be tolerable for patients.
You likely qualify if…
You likely don't qualify if…
You will visit the study center to receive as a single injection directly into your liver (guided by imaging). You will then receive intravenously once every 6 weeks for up to 6 months. Between treatments, you will have regular blood tests, imaging scans, and clinic visits to monitor how well the treatment is working and check for side effects. The study team will also ask you to undergo a tumor biopsy before treatment starts and potentially during treatment to understand how your cancer is responding.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
France
Phase
Safety & dosing
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Enrollment target
~27 participants
Started
November 2020
Primary completion
November 2022
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lambros Tselikas, MD
Gustave Roussy, Cancer Campus, Grand Paris
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.